EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.39
-0.03 (-0.88%)
▼
5d:
-5.83%
30d:
-16.5%
90d:
-12.63%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EVAX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: EVAX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.39, which is considered oversold relative to its 30-day fair value range of $3.46 to $4.03. The stock's valuation (Forward PE: 84.8) is in line with its historical norms (88.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVAX is in a uptrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+231.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EVAX is in a uptrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+231.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.46 -
$4.03
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 231.9% below Wall St target ($11.25)
- CAUTION: 5-day price weakness (-5.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.46 -
$4.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.23
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
84.75
Wall Street Target
$11.25
(+231.9%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
84.8 vs 88.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$3.35
(-1%)
2-Year Target
$3.30
(-3%)
3-Year Target
$3.26
(-4%)
3-Yr Target (if PE normalizes)
(PE: 85→88)
$3.39
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 84.8 to 88.1
Stabilization Target:
$3.52
(+4.0%)
PE Expansion Potential:
+4.0%
Share & Embed Analysis
Last updated: June 24, 2026 6:49 AM ET
Data refreshes hourly during market hours. Next update: 7:49 AM
Data refreshes hourly during market hours. Next update: 7:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |